PREVENT-AD Complete methods paper is available on here



Association of education with Aβ burden in preclinical familial and sporadic Alzheimer disease.  Gonneaud J., Bedetti C,  Pichet Binette A., Benzinger TLS, Morris J.C. Bateman R.J. Poirier J, Breitner JCS, Villeneuve S., DIAN Study Group and the PREVENT-AD Research Group, Neurology. 2020 Sep 15;95(11):e1554-e1564. Epub 2020 Aug 5.

doi: 10.1212/WNL.0000000000010314

Repetitive negative thinking is associated with amyloid, tau, and cognitive decline. Marchant L.N , Lovland L.R., Jones R, Pichet Binette A., Gonneaud J., Arenaza-Urquijo E. M., Chételat G., Villeneuve S., PREVENT-AD Research Group. Alzheimers Dement. 2020 Jul;16(7):1054-1064. Epub 2020 Jun 7.

doi: 10.1002/alz.12116

APOE4 Status Is Related to Differences in Memory-Related Brain Function in Asymptomatic Older Adults With Family History of Alzheimer’s Disease: Baseline Analysis of the PREVENT-AD Task Functional MRI Dataset. Rabipour  S, Rajagopal S, Yu E, Pasvanis S, Lafaille-Magnan ME, Breitner J, PREVENT-AD Research Group; Rajah MN, J Alzheimers Dis, 2020 May 26, Online ahead of print.

doi: 10.3233/JAD-191292

Amyloid and Tau Pathology Associations With Personality Traits, Neuropsychiatric Symptoms, and Cognitive Lifestyle in the Preclinical Phases of Sporadic and Autosomal Dominant Alzheimer’s Disease. Pichet Binette A, Vachon-Presseau É, Morris J, Bateman R, Benzinger T, Collins DL, Poirier J, Breitner JCS, Villeneuve S; Dominantly Inherited Alzheimer Network (DIAN); PREVENT-AD Research Group. Biol Psychiatry. 2020 Feb 6:S0006-3223(20)30058-5.

doi: 10.1016/j.biopsych.2020.01.023.

Association of Vascular Risk Factors With β-Amyloid Peptide and Tau Burdens in Cognitively Unimpaired Individuals and Its Interaction With Vascular Medication Use. Köbe T, Gonneaud J, Pichet Binette A, Meyer PF, McSweeney M, Rosa-Neto P, Breitner JCS, Poirier J, Villeneuve S; Presymptomatic Evaluation of Experimental or Novel Treatments for Alzheimer Disease (PREVENT-AD) Research Group. JAMA Netw Open. 2020 Feb 5;3(2):e1920780.

doi: 10.1001/jamanetworkopen.2019.20780.

Intermediate flortaucipir uptake is associated with Aβ-PET and CSF-tau in asymptomatic adults. McSweeney M, Pichet Binette A, Meyer PF, Gonneaud J, Bedetti C, Ozlen H, Labonté A, Rosa-Neto P, Breitner J, Poirier J, Villeneuve S; PREVENT-AD Research Group. Neurology. 2020 Feb 3.

doi: 10.1212/WNL.0000000000008905. [Epub ahead of print]

Morphometric network differences in ageing versus Alzheimer’s disease dementia. Pichet Binette A, Gonneaud J, Vogel JW, La Joie R, Rosa-Neto P, Collins DL, Poirier J, Breitner JCS, Villeneuve S, Vachon-Presseau E; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group. Brain. 2020 Feb 1;143(2):635-649.

doi: 10.1093/brain/awz414.


INTREPAD: a randomized trial of naproxen to slow progress of pre-symptomatic Alzheimer’s disease, Pierre François Meyer*, MSc; Jennifer Tremblay-Mercier*, MSc; Jeannie Leoutsakos, PhD; Cécile Madjar, MSc; Marie-Élyse Lafaille-Maignan, PhD; Melissa Savard, MSc; Pedro Rosa-Neto, MD, PhD; Judes Poirier, PhD**; Pierre Etienne, MD**; John Breitner, MD, MPH** for the PREVENT-AD research group. Neurology, 2019 Apr 5 [Epub ahead of print]

doi: 10.1212/WNL.0000000000007232.

No apparent effect of naproxen on CSF markers of innate immune activation, Meyer PF, Labonté A, Rosa-Neto P., Poirier, J. Breitner, J., & for the PREVENT-AD Research Group, BRIEF COMMUNICATION, Annals of Clinical and Translational Neurology, 06 June 2019.

Association of TLR4 with Alzheimer’s disease risk and presymptomatic biomarkers of inflammation, Justin Miron, Cynthia Picard, Marie-Élyse Lafaille-Magnan, Mélissa Savard, Anne Labonté, John Breitner, Pedro Rosa-Neto, Daniel Auld, Judes Poirier, for the PREVENT-AD research group, 4 June 2019, Alzheimer and dementia.

Aβ34 is a BACE1-derived degradation intermediate associated with amyloid clearance and Alzheimer’s disease progression. Filip Liebsch, Luka Kulic, Charlotte Teunissen, Adeola Shobo, Irem Ulku, Vivienne Engelschalt, Mark A. Hancock, Wiesje M. van der Flier, Peter Kunach, Pedro Rosa-Neto, Philip Scheltens, Judes Poirier, Paul Saftig, Randall J. Bateman, John Breitner, Christoph Hock & Gerhard Multhaup. Nature Communications volume 10, Article number: 2240 (2019)

MR-based age-related effects on the striatum, globus pallidus, and thalamus in healthy individuals across the adult lifespan. Tullo S, Patel R, Devenyi GA, Salaciak A, Bedford SA, Farzin S, Wlodarski N, Tardif CL; PREVENT-AD Research Group, Breitner JCS, Chakravarty MM. Hum Brain Mapp. 2019 Dec 15;40(18):5269-5288. Epub 2019 Aug 26.

doi: 10.1002/hbm.24771.

Proprotein convertase subtilisin/kexin type 9 (PCSK9) in Alzheimer’s disease: A genetic and proteomic multi-cohort study. Picard C, Poirier A, Bélanger S, Labonté A, Auld D, Poirier J; PREVENT-AD Research Group. PLoS One. 2019 Aug 22;14(8):e0220254. eCollection 2019.
doi: 10.1371/journal.pone.0220254

Association of PPP2R1A with Alzheimer’s disease and specific cognitive domains. Miron J, Picard C, Labonté A, Auld D, Breitner J, Poirier J; United Kingdom Brain Expression Consortium; PREVENT-AD research group. Neurobiol Aging. 2019 Sep;81:234-243. Epub 2019 Jul 2.

doi: 10.1016/j.neurobiolaging.2019.06.008.


Brain properties predict proximity to symptom onset in sporadic Alzheimer’s disease. Vogel JW, Vachon-Presseau E, Pichet Binette A, Tam A, Orban P, La Joie R, Savard M, Picard C, Poirier J, Bellec P, Breitner JCS, Villeneuve S; Alzheimer’s Disease Neuroimaging Initiative and the PREVENT-AD Research Group. Brain. 2018 Apr 23.

doi: 10.1093/brain/awy093.

Bi-directional Association of Cerebrospinal Fluid Immune Markers with Stage of Alzheimer’s Disease Pathogenesis. Meyer PF, Savard M, Poirier J, Labonté A, Rosa-Neto P, Weitz TM, Town T, Breitner, J; Alzheimer’s Disease Neuroimaging Initiative; PREVENT-AD Research Group. J Alzheimers Dis. 2018 Apr 11.

doi: 10.3233/JAD-170887.

A comparison of publicly available linear MRI stereotaxic registration techniques. Dadar M, Fonov VS, Collins DL; Alzheimer’s Disease Neuroimaging Initiative. Neuroimage. 2018 Jul 1;174:191-200. doi: 10.1016/j.neuroimage.2018.03.025. Epub 2018 Mar 13.

doi : 10.1016/j.neuroimage.2018.03.025

Subjective cognitive decline is associated with altered Default Mode Network connectivity in individuals with a family history of Alzheimer’s Disease, Verfaillie SCJ, Pichet Binette A, Vachon-Presseau E, Tabrizi S, Savard M, Bellec P, Ossenkoppele R, Scheltens P, van der Flier WM, Breitner JC, Villeneuve S for the PREVENT-AD Research Group. Biological Psychiatry: Cognitive Neurosciences and Neuroimaging. May 2018

doi: 10.1016/j.bpsc.2017

Proximity to Parental Symptoms Onset and Amyloid-β Burden in sporadic Alzheimer disease. Villeneuve S, Vogel JW, Gonneaud J, Pichet Binette A, Rosa-Neto P, Gauthier S, Bateman RJ, Fagan AM, Morris JC, Benzinger TL, Johnson SC, Breitner JC, Poirier J, for the Prevent-AD group. JAMA Neurology. 2018 May 1.

doi: 10.1001/jamaneurol.2017.5135.


Regionally specific changes in the hippocampal circuitry accompany progression of cerebrospinal fluid biomarkers in preclinical Alzheimer’s disease, Tardif CL, Devenyi G, Amaral RSC, Pelleieux S, Poirier J, Rosa-Neto P, Breitner J, Chakravarty MM; PREVENT-AD Research Group., Hum Brain Mapp. 2017 Nov 21.

doi: 10.1002/hbm.23897

Deficit in Central Auditory Processing as a Biomarker of Pre-Clinical Alzheimer’s Disease, Tuwaig, Miranda, Savard, Mélissa, Jutras, Benoît, Judes Poirier, Louis Collins, Pedro Rosa-Neto, David Fontaine and John C.S. Breitner for the PREVENT-AD Research Group, Journal of Alzheimer’s Disease, vol. 60, no. 4, pp. 1589-1600, 21 Aug 2017

doi: 10.3233/JAD-170545

Validation of a Regression Technique for Segmentation of White Matter Hyperintensities in Alzheimer’s Disease. Dadar M, Pascoal TA, Manitsirikul S, Misquitta K, Fonov VS, Tartaglia MC, Breitner J, Rosa-Neto P, Carmichael OT, Decarli C, Collins DL. IEEE Trans Med Imaging. 2017 Aug;36(8):1758-1768.

doi: 10.1109/TMI.2017.2693978

Odor identification as a biomarker of preclinical AD in older adults at risk. Lafaille-Magnan ME, Poirier J, Etienne P, Tremblay-Mercier J, Frenette J, Rosa-Neto P, Breitner JCS; PREVENT-AD Research Group. Neurology. 2017 Jul 25;89(4):327-335.

doi: 10.1212/WNL.0000000000004159


Alzheimer’s Progression Score’: Development of a Biomarker Summary Outcome for AD Prevention Trials J.-M. Leoutsakos, A.L. Gross , R.N. Jones, M.S. Albert, J.C.S. Breitner (2016) The Journal of Prevention of Alzheimer’s Disease – JPAD© Volume 3, Number 4, 2016

doi: 10.14283/jpad.2016

Rationale and Structure for a new Center for Studies on Prevention of Alzheimer’s Disease (StoP-AD) J.C.S. Breitner, J. Poirier, P.E. Etienne1, J.M. Leoutsakos for the PREVENT-AD Research Group (2016) The Journal of Prevention of Alzheimer’s Disease – JPAD© Volume 3, Number 4, 2016

doi: 10.14283/jpad.2016.121.


Test-retest resting-state fMRI in healthy elderly persons with a family history of Alzheimer’s disease. Orban P, Madjar C, Savard M, Dansereau C, Tam A, Das S, Evans AC, Rosa-Neto P, Breitner JC, Bellec P; PREVENT-AD Research Group. Sci Data. 2015 Oct 13;2:150043.

doi: 10.1038/sdata.2015.43.